Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × indibulin × Clear all
NCT01113970 2013-01-30

Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

Alaunos Therapeutics

Phase 1/2 Unknown
60 enrolled
Breast

Breast Neoplasms

NCT00726687 2012-07-19

Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors

Alaunos Therapeutics

Phase 1/2 Unknown
7 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡